Skip to Content
Merck
CN

Key Documents

View All Documentation

EHU074641

MISSION® esiRNA

targeting human CWF19L1

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

AACATCGGCACACATTGCTACCTTGCCCTGGCCAAAGGAGGCTTATCTGATGACCATGTCCTCATCCTGCCTATTGGACACTACCAGTCAGTGGTGGAGCTTTCAGCAGAGGTGGTAGAAGAGGTGGAGAAGTATAAGGCCACTCTGAGACGGTTCTTTAAGAGTCGAGGGAAATGGTGTGTTGTATTTGAGAGAAATTATAAGAGCCATCACCTCCAGCTACAGGTCATTCCTGTCCCAATCAGCTGCTCTACTACTGATGACATTAAAGATGCCTTCATTACCCAGGCACAGGAGCAGCAGATAGAGCTGTTGGAAATCCCAGAGCACTCTGACATCAAGCAGATTGCACAGCCAGGAGCAGCATATTTTTATGTTGAACTTGACACAGGAGAAAAGCTTTTCCACAGAATTAAAAAGAATTTTCCTTTGCAGTTTGGAAGGGAG

Ensembl | human accession no.

ENSG00000095485

NCBI accession no.

NM_018294

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... CWF19L1(55280)

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

10 - Combustible liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jin Shi et al.
Clinical and translational medicine, 10(1), 182-198 (2020-06-09)
Glioblastoma (GBM) is the most common primary tumor in the brain, and the median survival time for GBM patients is only about 14 months; therefore, there is an urgent need for new and more effective strategies. Since cell cycle disorder

Global Trade Item Number

SKUGTIN
EHU074641-50UG04061828391479
EHU074641-20UG04061828627219